Skip to main content
SpringerLink
Log in

Tumorvakzine

  • Living reference work entry
  • First Online:
Kompendium Internistische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 67 Accesses

Zusammenfassung

Das Immunsystem und seine Steuerungsfunktionen sind von zentraler Bedeutung für die Entstehung und den Verlauf von Tumorerkrankungen. Zahlreiche Tumorvakzinen wurden zur Verstärkung des Immunsystems entwickelt, um Tumorerkrankungen wirksam zu verhindern oder zu bekämpfen. Mittels Tumorvakzinen der ersten Generation wurden vereinzelt ermutigende klinische Ergebnisse erzielt. Aktuelle Studien prüfen optimierte Tumorvakzinen sowie deren Kombination mit anderen Tumor-Immuntherapien.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Burg SH der van, Arens R, Ossendorp F et al (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233

    Google Scholar 

  • Coulie PG, Van den Eynde BJ, van der Bruggen P et al (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146

    Article  CAS  Google Scholar 

  • Finn OJ (2018) The dawn of vaccines for cancer prevention. Nat Rev Immunol 18:183–194

    Article  CAS  Google Scholar 

  • Gouttefangeas C, Rammensee HG (2018) Personalized cancer vaccines: adjuvants are important, too. Cancer Immunol Immunother 67:1911–1918

    Article  CAS  Google Scholar 

  • Haen SP, Rammensee HG (2013) The repertoire of human tumor-associated epitopes – identification and selection of antigens and their application in clinical trials. Curr Opin Immunol 25:277–283

    Article  CAS  Google Scholar 

  • Hilf N, Kuttruff-Coqui S, Frenzel K et al (2018) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. https://doi.org/10.1038/s41586-018-0810-y. [Epub ahead of print]

  • Hodi FS, O’Day SJ, McDermott DF (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  Google Scholar 

  • Ilyas S, Yang JC (2015) Landscape of tumor antigens in T cell immunotherapy. J Immunol 195:5117–5122

    Article  CAS  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  CAS  Google Scholar 

  • Kenter GG, Welters MJ, Valentijn AR et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847

    Article  CAS  Google Scholar 

  • Melief CJ, van Hall T, Arens R et al (2015) Therapeutic cancer vaccines. J Clin Invest 125:3401–3412

    Article  Google Scholar 

  • Phetsouphanh C, Zaunders JJ, Kelleher AD (2015) Detecting antigen-specific T cell responses: from bulk populations to single cells. Int J Mol Sci 16:18878–11893

    Article  CAS  Google Scholar 

  • Romero P, Banchereau J, Bhardwaj N et al (2016) The human vaccines project: a roadmap for cancer vaccine development. Sci Transl Med 8:334ps9

    Article  Google Scholar 

  • Sahin U, Türeci Ö (2018) Personalized vaccines for cancer immunotherapy. Science 359:1355–1360

    Article  CAS  Google Scholar 

  • Sahin U, Derhovanessian E, Miller M et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222–226

    Article  CAS  Google Scholar 

  • Timmerman JM, Czerwinski DK, Davis TA et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526

    Article  CAS  Google Scholar 

  • Yee C, Riddell SR, Greenberg PD (2001) In vivo tracking of tumor-specific T cells. Curr Opin Immunol 13:141–146

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin III Hämatologie und Internistische Onkologie, Universitätsklinikum Regensburg, Regensburg, Deutschland

    Wolfgang Herr

  2. Universitätsklinikum Bonn, Medizinische Klinik III für Onkologie, Hämatologie, Immunonkologie und Rheumatologie, Universitätsklinikum Bonn, Bonn, Deutschland

    Peter Brossart

Authors
  1. Wolfgang Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Brossart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Herr .

Editor information

Editors and Affiliations

  1. Abt. Hämatologie und Onkologie, Universitätsklinikum Halle-Wittenberg Klinik und Poliklinik Innere Medizin IV, Halle, Sachsen-Anhalt, Germany

    Hans-Joachim Schmoll

Section Editor information

  1. Universitätsklinikum Bonn, Bonn, Germany

    Peter Brossart

  2. Berlin, Deutschland

    Sebastian Ochsenreither

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Herr, W., Brossart, P. (2021). Tumorvakzine. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_56-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46764-0_56-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46764-0

  • Online ISBN: 978-3-662-46764-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation